Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 4/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27141821 | 0.86 | ATR (0.42) | RXFP1ATRCYP17A1KCNQ4KCNQ5 | |
| SCHEMBL25137117 | 0.84 | ATR (0.40) | RXFP1ATRCYP17A1LMNAPOLB | |
| SCHEMBL25136736 | 0.84 | ATR (0.40) | RXFP1ATRCYP17A1MAPKAPK2LCK | |
| SCHEMBL25136697 | 0.83 | ATR (0.40) | RXFP1ATRCYP17A1KCNQ4KCNQ5 | |
| SCHEMBL31323628 | 0.79 | MAPKAPK2 (0.40) | ATRCYP17A1POLBMAPKAPK2LCK | |
| SCHEMBL23608433 | 0.77 | SMARCA2 (0.44) | RXFP1ATRCYP17A1MAPKAPK2LCK | |
| SCHEMBL29818315 | 0.77 | SMARCA2 (0.44) | RXFP1ATRCYP17A1MAPKAPK2LCK | |
| SCHEMBL25136933 | 0.76 | CYP17A1 (0.36) | RXFP1ATRCYP17A1KCNQ4KCNQ5 | |
| SCHEMBL25136815 | 0.76 | ATR (0.40) | RXFP1ATRCYP17A1MAPKAPK2LCK | |
| SCHEMBL23592933 | 0.76 | ATF1 (0.41) | RXFP1ATRLMNAPOLBCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | RXFP1 4480/4885ATR 1225/4885CYP17A1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.